Dr. Trevor Martin is the CEO and co-founder of Mammoth Biosciences, which addresses challenges across healthcare, agriculture, environmental monitoring, biodefense, and more through discovery of novel CRISPR systems to power the next generation of CRISPR-based synthetic biology products. Ursheet Parikh is a partner at the venture capital firm Mayfield, where he co-leads the Human and Planetary Health investment practice, which includes an investment in Mammoth. In this conversation with Stanford adjunct lecturer Ravi Belani, Martin and Parikh share their advice for building a platform biotech company with staying power.
Related
Josh Wolfe,
Lux Capital
Investing at the Cutting Edge [Entire Talk]
The entrepreneurs that attract venture capital investments think differently and tackle big problems that few others are willing to
Josh Wolfe,
Lux Capital
Investing at the Cutting Edge [Entire Talk]
The entrepreneurs that attract venture capital investments think differently and tackle big problems that few others are willing to
Rahul Roy-Chowdhury,
Grammarly
Responsible AI Innovation [Entire Talk]
AI tools are the future of technology. People have the power to ensure AI benefits us.
Rahul Roy-Chowdhury,
Grammarly
Responsible AI Innovation [Entire Talk]
AI tools are the future of technology. People have the power to ensure AI benefits us.
Claire Hughes Johnson,
Stripe
Scaling Operations and People [Entire Talk]
Build a company that is ready to scale with a strong foundation of values, well-built operating structures, and a complementary team.
Claire Hughes Johnson,
Stripe
Scaling Operations and People [Entire Talk]
Build a company that is ready to scale with a strong foundation of values, well-built operating structures, and a complementary team.
